M
Maijing Gene
Maijing Gene is a gene detection technology company that specializes in R&D, production, and sales of molecular diagnostic products
About Maijing Gene
Maijing Gene, established in 2015, is a medical technology company specializing in molecular diagnostic products. The company's headquarters are in Guangzhou International Bio Island, with additional branches in East, Central, and North China, and a research and development center in Silicon Valley, USA. The legal representative, Chairman, and CEO is Yang Dongcheng.
The firm focuses on the application of second-generation high-throughput sequencing technology in the field of precision medicine. Its business model encompasses both the sale of in-vitro diagnostic (IVD) products and the provision of medical testing services. The company serves a client base that includes patients, doctors, and medical institutions, aiming to provide comprehensive and convenient services. Maijing Gene's operations are supported by technical platforms such as qPCR, Sanger sequencing, and Next-Generation Sequencing (NGS). The company has established a third-party medical laboratory in Guangzhou to facilitate its testing services.
Maijing Gene has developed a range of diagnostic products for various cancers, including lung cancer, colorectal cancer, and other solid tumors. A significant milestone was achieved in October 2022, when its multi-gene companion diagnostic kit for lung cancer (MaiFeiJie®) received approval from the National Medical Products Administration (NMPA). This was followed by the approval of a rapid detection kit for colorectal cancer diagnostics (MaiChangJie®) in January 2024 and an NGS companion diagnostic kit (JingJianXin™) in August 2024. These approvals position Maijing Gene as a company with both NGS and PCR-based multi-gene companion diagnostic products for tumors in China.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Dec 2022 | $29M | $115M | Gongqingcheng Angu Fuge Investment · Hongtu Runda · Efung Capital · Mercedes-Benz Capital | ↗ |
| SERIES B✓Equity / VC | Jan 2020 | $14M | $57M | CASH Capital · Shenzhen Capital Group · Guoke Jiahe (Beijing) Investment Management | — |
Growth signals
Latest recorded traffic for Maijing Gene is 60 monthly website visits, down 79.3% over the last three months. Maijing Gene's team declined 9.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Maijing Gene in the Guangzhou ecosystem
The Maijing Gene office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Shenzhen Capital Group- GMGuoke Jiahe (Beijing) Investment Management
- CCCASH Capital
Series B and later5 investors entered at this stage
- GIGongqingcheng Angu Fuge Investment
- HRHongtu Runda
- ECEfung Capital
- MCMercedes-Benz Capital
- JCJiuyou Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Maijing Gene on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Maijing Gene’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








